Literature DB >> 9748149

Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma.

Y Oda1, A Sakamoto, N Shinohara, T Ohga, T Uchiumi, K Kohno, M Tsuneyoshi, M Kuwano, Y Iwamoto.   

Abstract

The Y-box-binding protein, YB-1, is a member of the DNA-binding protein family. It binds to the Y-box, an inverted CCAAT box, in the promoter region of the human multidrug resistance 1 gene, which encodes P-glycoprotein (P-gp). Nuclear localization of YB-1 protein has been reported to be associated with the intrinsic expression of P-gp in human breast cancer. We studied the immunohistochemical expression of YB-1 protein in 69 untreated biopsy specimens of conventional osteosarcomas and compared it with the expression of P-gp. Furthermore, cell proliferation, as determined by the MIB-1-labeling index (MIB-1-LI), was measured by immunohistochemistry. In all 69 untreated osteosarcomas, YB-1 protein was expressed in the cytoplasm. In 32 of 69 (46%) cases, YB-1 was also localized in the nucleus. The expression of P-gp was evident in 23 of these 32 cases, and there was a significant correlation between the nuclear expression of YB-1 and P-gp expression (P < 0.0001). Chondroblastic osteosarcoma expressed YB-1 in the nucleus more frequently (eight of nine cases) than did other types of osteosarcoma, whereas P-gp was also frequently expressed in chondroblastic subtype. There was no correlation between the nuclear expression of YB-1 and histological grade. The MIB-1-LI was significantly higher in cases showing the nuclear expression of YB-1 (MIB-1-LI averaged 22.56 in cases with only cytoplasmic expression of YB-1 but averaged 28.20 in cases with cytoplasmic and nuclear expression of YB-1; P = 0.0477). In human osteosarcoma, nuclear localization of YB-1 protein was associated with the expression of P-gp, suggesting that YB-1 could be a prognostic marker for multidrug resistance in osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748149

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Characterization of the 5'-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein.

Authors:  Takao Fukuda; Megumi Ashizuka; Takanori Nakamura; Kotaro Shibahara; Katsumasa Maeda; Hiroto Izumi; Kimitoshi Kohno; Michihiko Kuwano; Takeshi Uchiumi
Journal:  Nucleic Acids Res       Date:  2004-01-29       Impact factor: 16.971

2.  A novel recombinant papillomavirus genome enabling in vivo RNA interference reveals that YB-1, which interacts with the viral regulatory protein E2, is required for CRPV-induced tumor formation in vivo.

Authors:  Natalie Leiprecht; Ekaterina Notz; Johanna Schuetz; Juliane Haedicke; Frank Stubenrauch; Thomas Iftner
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

3.  Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.

Authors:  Ranajoy Chattopadhyay; Soumita Das; Amit K Maiti; Istvan Boldogh; Jingwu Xie; Tapas K Hazra; Kimitoshi Kohno; Sankar Mitra; Kishor K Bhakat
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

Review 4.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

5.  Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development.

Authors:  Gabriel Glockzin; Klaus Mantwill; Karsten Jurchott; Alexandra Bernshausen; Axel Ladhoff; Hans-Dieter Royer; Bernd Gansbacher; Per Sonne Holm
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer.

Authors:  Wenxiu Xie; Junlan Yang; Yuean Cao; Chaosheng Peng; Haoyong Ning; Fan Zhang; Junhao You
Journal:  Tumour Biol       Date:  2011-10-04

7.  Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Authors:  Jennifer H Law; Yvonne Li; Karen To; Michelle Wang; Arezoo Astanehe; Karen Lambie; Jaspreet Dhillon; Steven J M Jones; Martin E Gleave; Connie J Eaves; Sandra E Dunn
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

8.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Authors:  Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe P Roux; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-11-27       Impact factor: 6.466

9.  Cellular localization of Y-box binding protein 1 in brain tissue of rats, macaques, and humans.

Authors:  Bernadette Unkrüer; Anton Pekcec; Christina Fuest; Andrea Wehmeyer; Maria S Balda; Anja Horn; Wolfgang Baumgärtner; Heidrun Potschka
Journal:  BMC Neurosci       Date:  2009-03-26       Impact factor: 3.288

10.  Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

Authors:  Edgar Dahl; Abdelaziz En-Nia; Frank Wiesmann; Renate Krings; Sonja Djudjaj; Elisabeth Breuer; Thomas Fuchs; Peter J Wild; Arndt Hartmann; Sandra E Dunn; Peter R Mertens
Journal:  BMC Cancer       Date:  2009-11-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.